Description: WuXi Biologics (Cayman) Inc., an investment holding company, provides discovery, research, development, and manufacturing of biologics services. It offers clinical and commercial manufacturing, assay, formulation and process development, assay and process validation, protein, monoclonal antibodies and cGMP drug substances manufacturing, lot release testing, stability studies, drug product formulation, fill and finish, and regulatory support services. The company also provides consultation services for biopharmaceutical technology, sales and marketing, and international sales contracting service; and produces and sells medicals. It serves pharmaceutical and biotechnology companies. WuXi Biologics (Cayman) Inc. has a strategic collaboration with Bioasis Technologies Inc. to develop and manufacture xB3-001 to treat cancer; CANbridge Pharmaceutical Inc. to develop and commercialize a portfolio of iotherapeutics for the treatment of rare diseases; ABL Bio Corporation to develop bispecific antibodies; AC Immune SA for biologics discovery, development, and manufacturing; Oxford BioTherapeutics for developing bispecific antibodies; and Amicus Therapeutics, Inc. The company was founded in 2014 and is headquartered in Wuxi, China. WuXi Biologics (Cayman) Inc. is a subsidiary of WuXi Biologics Holdings Limited.
Home Page: www.wuxibiologics.com
No. 108, Meiliang Road
Wuxi,
214092
China
Phone:
86 510 8183 1205
Officers
| Name | Title |
|---|---|
| Dr. Ge Li Ph.D. | Founder & Chairman |
| Dr. Zhisheng Chen | CEO & Exec. Director |
| Dr. Weichang Zhou Ph.D. | Pres of Global Biologics Devel. & Operations, CTO and Exec. Director |
| Mr. Ming Tu | CFO & Exec. VP |
| Ms. Tang Shaogui M.B.A. | VP and Head of Global Communications, Operations, Marketing & ESG |
| Dr. Jijie Gu | Exec. VP & Chief Scientific Officer |
| Ms. Eileen Wang | IR Sr. Director |
| Ms. Cong Ding J.D. | VP & Head of Legal Department |
| He Wang | Chief Compliance Officer, Sr. VP & Head of Global Compliance and Risk Management |
| Ms. Li Xiong | VP & Head of Global HR |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 30.1205 |
|---|---|
| Trailing PE: | 55 |
| Price-to-Book MRQ: | 5.9181 |
| Price-to-Sales TTM: | 2.1061 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 10593 |